Swiss company launches rapid test to determine Covid-19 severity
Septic shock is one of the major complications of Covid-19.
Keystone / Pablo Gianinazzi
Lausanne-based medical technology firm Abionic has created the first rapid blood test to help doctors decide whether Covid-19 patients require treatment in intensive care units.
This content was published on
2 minutes
Keystone-SDA/jdp
Español
es
COVID-19: Prueba rápida suiza detecta gravedad de pacientes
According to a presentationExternal link by Abionic, the Covid-19 Severity Score test uses a small blood sample from the fingertip to determine how serious the disease is and how likely it is to worsen. Physicians receive the test results within five minutes and could then decide whether a patient should be admitted to intensive care, transferred to a general hospital ward or discharged from the hospital.
The test is intended to ease the burden on healthcare workers and intensive care units that are reaching capacity in some countries with high numbers of Covid-19 patients.
Abionic adapted the diagnostics process it developed for the detection of sepsis, a life-threatening complication of bacterial and viral infections, for use in Covid-19 in order to provide faster results. The Covid-19 severity test is based on the “sequential organ failure assessment score” (SOFA score), which is tracked by hospitals to determine a patient’s status in intensive care units based on organ functioning.
“Already in March of this year, we noticed in many different publications that one of the most frequent causes of death in Covid-19 patients was indeed bacterial sepsis,” Abionic CEO Nicolas Durand told Reuters news agency.
The test has been validated in clinical studies involving several hundred patients in various countries and hospitals and has received approval for use in Europe.
Founded in 2010 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPFL), Abionic distributes its tests and devices mainly in Europe. The company has received almost CHF37 million ($40.7 million) from investors in three rounds of financing.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Is artificial intelligence an advantage or a disadvantage for workers?
What is your experience with AI at work? Have you already used it? Has it helped you work better? Or has it caused you more stress, more work or caused you to lose your job? Tell us about your experiences!
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
This content was published on
As money is poured into the search for a silver bullet to Covid-19, some experts warn that the pandemic could also worsen the antibiotics crisis.
The Swiss biotech shaking up the antibiotics model
This content was published on
Family-owned Debiopharm says it’s time to treat the life-saving medicine like insurance if we want to avoid another pandemic.
Intensive care staff exhausted as Covid numbers rise
This content was published on
Intensive care workers are going into the second wave of the coronavirus pandemic exhausted, the Swiss Society of Intensive Care Medicine has warned.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.